
Trial comparing oral ponesimod versus teriflunomide (Aubagio) in relapsing multiple sclerosis will evaluate annualized relapse rate as well as other disease activity measures.

Trial comparing oral ponesimod versus teriflunomide (Aubagio) in relapsing multiple sclerosis will evaluate annualized relapse rate as well as other disease activity measures.

Researchers at Kaiser Permanente Washington conducted a qualitative pilot study to understand the experiences and decision-making women face as they contemplate the use of antinausea medications during pregnancy.

In this video, Ryan Forrey, PharmD, MS, FASHP is the Senior Manager of Market Development for Hazardous Drugs at BD, discusses USP 800 and surface contamination monitoring.

The Pharmacy Times Salary and Job Satisfaction Survey shows that workload, management, and work/life balance were the 3 top drivers of dissatisfaction.

Tomorrow, pharmacists will be in the spotlight. It is also an opportunity for them to express pride in their work and share aspects of the job that keep them motivated.

Glucagon-like peptide-1 receptor agonists have been gaining popularity to treat diabetes. Does this one provide advantages over competitors?

In response to a growing demand for personalized medicine, the Midwestern University Chicago College of Pharmacy earlier this week announced the establishment of a Pharmacometrics Center of Excellence on the school’s Downers Grove Campus.

A newly-developed biomedical device may help prevent chemotherapy from spreading away from the targeted tumor.

Top news of the week from Specialty Pharmacy Times.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

The rate of palliative care in patients with multiple sclerosis to have died in US hospitals increased from 7.7% to 58.8% over 10 years

National Pharmacist Day, celebrated annually on January 12, honors pharmacists across different specialties and in every setting by recognizing the impact they have in health care.

On National Pharmacist Day, share your #APharmacistIs story on social media.

USP General Chapter , which was published by the United States Pharmacopeial Convention and updated most recently in December 2017, sets forth guidelines for the handling of hazardous drugs in the health care setting with the goal of promoting safety for patients and health care workers.

Study shows the United States spends more on health care on a per capita basis than other developed countries, mostly due to higher prices.

High consumption of sugary beverages has previously been linked to obesity, diabetes, and some types of cancer.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Patients with hepatitis C virus treated with direct acting antiviral drugs showed successful long-term outcomes regardless of receiving opioid substitution therapy for drug addiction.

Patients receiving anticoagulation that need to have an invasive procedure performed may require a temporary interruption in their anticoagulation therapy to limit bleed risk.

Using a drug that increases GABA synthesis and possibly escalates intraneuronal dopamine in a population that is more likely to have behavior health concerns may prove to be an unsafe option.

An FDA-approved mobile application for adults with opioid use disorder (OUD) is now available by prescription. Pear Therapeutics’ reSET-O app aims to increase retention for adults who are in outpatient treatment programs.

The world is rapidly moving towards the adoption and seamless integration of artificial intelligence (AI), including machine learning as a subset of AI, throughout our daily lives.

A newly study published study aimed to distinguish between uninfected cells and latently infected cells, with hopes that eradicating the latent reservoirs could lead to a cure for the disease.

A survey of California 2017 enrollees estimates how drops in enrollment may affect premium increases.

Officials with the FDA have granted Breakthrough Therapy designation to Novartis’ crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Combination of glecaprevir and pibrentasvir for hepatitis C virus genotype 3 effective over an 8-week treatment duration.